ErbB4/Her4 was detected in immersion fixed MCF‑7 human breast cancer cell line using Goat Anti-Human ErbB4/Her4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1131) at 10 µg/mL for 3 hours at room ...read more
Mouse myeloma cell line NS0-derived recombinant human ErbB4/Her4 Gln26-Arg649 Accession # Q15303
Detects human ErbB4/Her4 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross‑reactivity with recombinant mouse ErbB4 is observed, and less than 1% cross-reactivity with recombinant human (rh) ErbB2, rhErbB3, and rhEGF R is observed.
Details of Functionality
ActivityAssaywCitation not found None None None
Test in a species/application not listed above to receive a full credit towards a future purchase.
ErbB4, also called Her4 (human epidermal growth factor receptor 4), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain, and several breast carcinomas. ErbB4 ligands include the neuregulins, beta-cellulin and heparin-binding EGF-like growth factor (HB-EGF). Monomeric ErbB4 binds its ligands with low affinity. Typically, heterodimerization with ErbB2 forms the high affinity receptor complex. However, ErbB4 has also been shown to heterodimerize with both ErbB1 and ErbB3. It has been suggested that the identity of the ligand may influence the dimerization partner. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid (aa) signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. Interestingly, this same three amino acid signal has been found in ErbB4 and ErbB1 (EGF R). Several ErbB4 isoforms exist. Two of these differ in the presence of juxtamembrane extracellular sequences which regulate the ability of TACE (TNF-alpha converting enzyme) to proteolytically cleave ErbB4 from the cell surface. These isoforms exhibit tissue-specific expression. Another isoform lacks the phosphoinositide 3-kinase activation sequence present in the ErbB4 cytoplasmic domain. Human ErbB4 consists of 1308 amino acids with a 25 aa signal sequence, a 626 aa extracellular domain, a 24 aa transmembrane region, and a 633 aa cytoplasmic domain. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer.
Plowman, G.D. et al. (1993) Proc. Natl. Acad. Sci. USA 90:1746.
Elenius, K.et al. (1997) J. Biol. Chem. 272:26761.
Elenius, K. et al. (1999) Oncogene 18:2607.
Rio, C. et al. (2000) J. Biol. Chem. 275:10379.
Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
Sundaresan, S. et al. (1998) Endocrinology 139:4756.
Schaefer, G. et al. (1999) J. Biol. Chem. 274:859.
Schlessinger, J. (2000) Cell 103:211.
Daly, R.J. (1999) Growth Factors 16:255.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our ErbB4/Her4 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.